Contact
Please use this form to send email to PR contact of this press release:
Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy
TO:
Please use this form to send email to PR contact of this press release:
Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy
TO: